my account
  Loading... Please wait...


Diabetes is a disease characterized by either the inability to produce enough insulin or a lack of cellular response to insulin. The resulting high blood sugar levels lead to myriad health issues including cardiovascular disease, vision loss, nerve damage, and kidney disease. Current therapies for glycemic control include metformin, sulfonylureas and PPAR-γ agonists. Newer modalities targeting the incretin axis include dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like peptide-1 (GLP-1) agonists. A novel method for controlling glucose via the kidneys is inhibition of sodium glucose co-transporter 2 (SGLT2).

View All Diabetes Reagents


  • A-769662

    Potent and reversible AMPK allosteric activator that inhibits fatty acid biosynthesis

  • Fatostatin

    Fatostatin blocks adipogenesis by inhibiting the activation of SREBP

View All Adipogenesis Reagents


  • Dorsomorphin

    Potent and selective inhibitor of AMPK


    AICAR is an activator of AMPK

  • Metformin

    Inhibits gluconeogenesis by activating the AMPK pathway

View All AMPK Reagents


  • Alsterpaullone

    Alsterpaullone is a potent inhibitor of GSK-3β

  • CHIR-99021

    Potent and selective inhibitor of GSK-3β

  • SB-216763

    Potent and selective inhibitor of GSK-3α/β

View All GSK Reagents


View All PPAR Reagents